02137

0.9952.58%
ZH

Zhi Hong

Co-founder, Executive Chairman of the Board & CEO

Dr. Zhi Hong, PhD, co-founded Brii Biosciences Limited in 2018 and serves as its Executive Chairman of the Board Since March 24, 2021, Chief Executive Officer & Executive Director since February 23, 2018. Prior to starting Brii Bio, Dr. Hong served as Senior Vice President and Head of the Infectious Disease Center of Excellence for Drug Discovery at GlaxoSmithKline. Dr. Hong served as Chief Scientific Officer and Executive Vice President of Research of Ardea Biosciences, Inc. (Formerly, Intrabiotics Pharmaceuticals Inc.) from December 22, 2006 to March 2007. Previously, Dr. Hong served as a Vice President and Head of Research at Valeant Pharmaceuticals International since joining it in 2000. During his tenure with Valeant, he directed both the virology and cancer/immunology programs and held leadership positions on the HBV, HCV and HIV project teams that led to four US investigational new drug (IND) applications in six years. He served as a Director of ViiV Healthcare Limited from October 30, 2009 to March 15, 2018. Prior to Valeant, he also held various research and management roles at Schering-Plough Research Institute. He is an expert in viral replication and a renowned investigator in the mechanism of action of ribavirin and interferon. He has authored/co-authored close to 100 research publications in peer-reviewed journals and has been involved in the issuance and/or publishing of more than 40 patents. He serves as a Director of ViiV Healthcare Limited. He served as a Director of Anacor Pharmaceuticals Inc. from 2009 to May 25, 2011. Dr. Hong obtained his Bachelor of Science in Biochemistry from Fudan University in China in July 1985 and a Ph.D. in Biochemistry from State University of New York in the United States in January 1992.

Positions